JNJ-63898081

N/A

Report date: 2026/03/19 16:46:53

Base Information

Drug NameJNJ-63898081

Drug Alias NameJNJ-63898081JNJ-8081

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD3

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesJanssen Research & Development Llc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A